Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Banco Santander

Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.

About to Buy Penny Stocks?  Look at These 2 Companies First

Funding to Support the Company’s Commercialization Plans for Twirla  ®

Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover Target

AbbVie

Amarin Corporation Plc

Esperion Therapeutics

Eli Lilly

Merck

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

4 Dates Biotech Investors Should Circle in February

Agile Therapeutics' Market Potential, And Other News: The Good, Bad, And Ugly Of Biopharma

Agile: Recent AdCom Decisions Further Support Twirla Approval

Agile Therapeutics: 400%+ Upside

Air Industries Group

Journey Medical Corp

Microbot Medical

Cassava Sciences Inc

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

PRINCETON, N.J., Jan.  02, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan has over 35 years of experience in the healthcare industry working in finance, sales, marketing, business development, and managed markets.

Agile Therapeutics Strengthens Commercial Leadership Team

Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying Opportunity

Cigna

Cardinal Health

Immunomedics

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

AbbVie, Cigna and Other Health Care Stocks With Recent Golden Crosses

PRINCETON, N.J., Nov.  14, 2019  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla® (levonorgestrel/ethinyl estradiol) transdermal system, an investigational combined hormonal contraceptive patch, from November 16, 2019 to February 16, 2020.

Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

Agile Therapeutics: Stock Hits 52-Week Low And A Near 52-Week High Around Twirla's AdCom

Shares of Agile Therapeutics Inc. AGIL, +0.00% rocketed nearly 4-fold (up 270%) in very active afternoon trading, after the women's healthcare company said a U.S.

Agile Therapeutics' stock rockets nearly 4-fold after contraceptive patch Twirla gets favorable FDA committee nod

Agile Therapeutics Inc (NASDAQ: AGRX) shares were galloping higher Thursday in a notable turnaround following the precipitous drop they experienced earlier in the week.

Agile Therapeutics Rallies After FDA Panel Backs Contraceptive Patch

Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval

Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

FDA Advisory Committee Meeting for Twirla® NDA Scheduled for October 30, 2019

Agile Therapeutics Reports Third Quarter 2019 Financial Results

Is  (AGRX) Outperforming Other Medical Stocks This Year?

Is Agile Therapeutics (AGRX) Outperforming Other Medical Stocks This Year?

Agile Therapeutics (AGRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agile Therapeutics (AGRX) Upgraded to Buy: Here's What You Should Know

Barrett Business Services

Boot Barn Hlds

Hibbett Sports

Construction Partners

Due to their limited international exposure, domestic firms offer more protection than their large- and mid-cap counterparts during economic upheavals.

Trade Worries Resurface! Buy These 5 U.S.

Agile Therapeutics (AGRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Agile Therapeutics (AGRX) Upgraded to Strong Buy: Here's What You Should Know

Agile's contraceptive product candidate, Twirla, has an FDA AdCom scheduled for October 30th. Investors should have a game plan for their AGRX position as we approach this powerful binary event.

Agile Therapeutics: Preparing For The AdCom And PDUFA Run-Up

PRINCETON, N.J., Sept.  06, 2019  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at two upcoming investor conferences in New York City, where he will provide an overview of the company’s business and upcoming milestones.

Agile Therapeutics to Present at Upcoming Investor Conferences

Agile Therapeutics recently announced the FDA has scheduled an Advisory Committee to review Twirla's NDA on October 30th.

Agile Therapeutics: Twirla AdCom Provides Investors A Bridge To PDUFA

CannTrust Holdings

Himax Tech

Northern Oil and Gas

Sientra

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks to Buy Priced Below $10 With Monster Upside Potential

News for Agile Therapeutics Stock (AGRX)